Unleashing the potential of genetic medicines with novel delivery vehicles

Liberate is using automation, in vivo high-throughput screening, and machine learning to accelerate discovery of novel extrahepatic delivery vehicles

Our mission is to liberate patients from genetic disorders by advancing non-viral delivery technologies for nucleic acid cargoes such as ASOs, siRNAs, mRNAs, and encoded gene editors.

High throughput in vivo screening of barcoded cargoes
Machine learning to identify novel lipids and novel LNP formulations
Expansion to non-lipid technologies

Enhanced delivery to disease relevant tissues

At Liberate Bio, we are enabling precise delivery to disease relevant tissues to realize the full potential of genetic medicines. Seeded by Khosla Ventures, we were founded by leaders in the nucleic acid therapeutics and delivery fields, including Professor Michael Mitchell of the University of Pennsylvania and Nessan Bermingham of Khosla Ventures.

Our Team

Shawn Davis
CEO
Walter Strapps
CSO
Stephen Scully
CO-FOUNDER
HEAD OF STRATEGY & OPERATIONS
Nessan Bermingham
CO-FOUNDER
KHOSLA VENTURES
Michael Mitchell
CO-FOUNDER
UNIVERSITY OF PENNSYLVANIA
Theresa M. Reineke
Co-founder
University of Minnesota

Latest News

05.31.23 / Business Wire

Liberate Bio Announces Expansion of its Leadership Team

READ MORE
02.23.23 / Biobuzz

Liberate Bio: Pushing into the Future of Therapeutic Vectors

READ MORE
01.17.23 / PHARMAPHORUM

Taking an ‘upside-down’ approach to mRNA delivery

READ MORE
12.08.22 / GENENGNEWS.COM

Liberate Bio is Bringing Precision Delivery to Genetic Medicines

READ MORE
10.21.22 / BioWorld

Deliver, but not to the liver: Liberate Bio developing targeted nucleic acid delivery technologies

READ MORE
Liberate is building a team to deliver on our vision. We are looking for the right biologists, chemists, and administrative team members.
If you are interested in joining us, please contact:
[email protected]
Liberate is pursuing a hybrid business model with an internal pipeline and partnered programs. Partnerships may be structured around delivery vehicle, target tissue, or indication.
If you are interested in partnering with us, please contact:
[email protected]